> After a median follow-up of 10.5 months, the estimated rate of overall survival at 12 months was 69.2% in the pembrolizumab-combination group versus 49.4% in

> After a median follow-up of 10.5 months, the estimated rate of overall survival at 12 months was 69.2% in the pembrolizumab-combination group versus 49.4% in the placebo-combination group. Seriously groundbreaking. This is a once-in-a-decade paper. [1] [1] http://www.nejm.org/doi/full/10.1056/NEJMoa1801005?query=featured_home& http://www.nejm.org/doi/full/10.1056/NEJMoa1801005?query=fea...